Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

C Montefiori, David; Karnasuta, Chitraporn; Huang, Ying; Ahmed, Hasan; Gilbert, Peter; S de Souza, Mark; McLinden, Robert; Tovanabutra, Sodsai; Laurence-Chenine, Agnes; Sanders-Buell, Eric; Anthony Moody, M; Bonsignori, Mattia; Ochsenbauer, Christina; Kappes, John; Tang, Haili; Greene, Kelli; Gao, Hongmei; C LaBranche, Celia; Andrews, Charla; R Polonis, Victoria; Rerks-Ngarm, Supachai; Pitisuttithum, Punnee; Nitayaphan, Sorachai; Kaewkungwal, Jaranit; G Self, Steve; W Berman, Phillip; Francis, Donald; Sinangil, Faruk; Lee, Carter; Tartaglia, Jim; L Robb, Merlin; F Haynes, Barton; L Michael, Nelson; H Kim, Jerome

doi:10.1093/infdis/jis367

Public

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Shared by NobleBlocks on Aug 1, 2012 • 12:00 AM UTC

Authors:

David C Montefiori

Chitraporn Karnasuta

Ying Huang

Abstract

BACKGROUND: A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with a bivalent gp120 protein boost (AIDSVAX B/E), provided modest protection against HIV-1 infection in a community-based population in Thailand ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!